NCT00620867已完成4 期
A Study of the Efficacy and Tolerability of Once Daily Celebrex (Celecoxib) and Three Times Daily Ibuprofen vs. Placebo in the Treatment of Subjects With Osteoarthritis of the Knee
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.1 个研究点 分布在 1 个国家目标入组 393 人开始时间: 2002年10月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 393
- 试验地点
- 1
- 主要终点
- Change from baseline in patient's assessment of arthritis pain according to visual analogue scale (VAS)
研究概览
简要总结
To compare the efficacy and safety of celecoxib versus ibuprofen in subjects with osteoarthritis (OA) of the knee.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 40 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Aged >= 40 years old
- •Diagnosed with OA of the knee according to the American College of Rheumatology and OA in flare state at baseline visit
- •Functional capacity class of I-III
排除标准
- •Inflammatory arthritis or gout or pseudo-gout with acute flare within the past 2 years (subjects with fibrositis or fibromyalgia will not be excluded)
- •Acute joint trauma at index joint within the past 3 months with active symptoms
- •Score of >=20 on PHQ-9 or score of >=1 on PHQ-9 item i
- •Use of mobility assisting device for <6 weeks or use of walker
研究组 & 干预措施
Ibuprofen
Experimental
干预措施: Ibuprofen (Drug)
Celecoxib
Experimental
干预措施: celecoxib (Drug)
placebo
Placebo Comparator
干预措施: placebo (Other)
结局指标
主要结局
Change from baseline in patient's assessment of arthritis pain according to visual analogue scale (VAS)
时间窗: Week 6
次要结局
- Change from baseline in patient's and physician's global assessment of pain(Weeks 2 and 6)
- Pain Satisfaction Scale(Days 1-7)
- Physical examination(Week 6)
- Change from baseline in Western Ontario and McMaster Universities Osteoarthritis Index(Week 6)
- Laboratory test results(Week 6)
- Change from baseline in patient's assessment of arthritis pain according to VAS(Week 2)
- Vital signs(Weeks 2 and 6)
- Adverse events(Weeks 2 and 6)
- Patient Health Questionnaire (PHQ-9)(Week 6)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
4 期
Efficacy and Safety of Celecoxib Versus Ibuprofen in the Treatment of Osteoarthritis of the Knee (Europe)Osteoarthritis, KneeNCT00630929Pfizer's Upjohn has merged with Mylan to form Viatris Inc.388
已完成
3 期
Etoricoxib vs. Diclofenac in OA (0663-805)(COMPLETED)OsteoarthritisNCT00542087Organon and Co516
已完成
4 期
Safety and Efficacy of Celecoxib Versus Naproxen in the 6-month Treatment of Knee OsteoarthritisOsteoarthritis, KneeNCT00643799Pfizer's Upjohn has merged with Mylan to form Viatris Inc.586
已完成
4 期
Safety and Efficacy of Celecoxib Versus Placebo in the Treatment of Knee Osteoarthritis in Patients Who Were Unresponsive to Naproxen and IbuprofenOsteoarthritis, KneeNCT00638807Pfizer's Upjohn has merged with Mylan to form Viatris Inc.388
已完成
3 期
Compare Celecoxib and Ibuprofen Sr In The Management Of Acute Pain Post Orthopedic Or Gynecological SurgeryPain, PostoperativeNCT00150280Pfizer's Upjohn has merged with Mylan to form Viatris Inc.132